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Introduction. Cryoballoon (CB) ablation has emerged as a novel treatment for pulmonary vein isolation (PVI) for patients
with paroxysmal atrial fibrillation (PAF). The second-generation Arctic Front Advance (ADV) was redesigned with technical
modifications aiming at procedural and outcome improvements.We aimed to compare the efficacy of the two different technologies
over a long-term follow-up.Methods. A total of 120 patients with PAF were enrolled. Sixty patients underwent PVI using the first-
generation CB and 60 patients with the ADV catheter. All patients were evaluated over a follow-up period of 2 years. Results. There
were no significant differences between the two groups of patients. Procedures performed with the first-generation CB showed
longer fluoroscopy time (36.3 ± 16.8 versus 14.2 ± 13.5min, resp.; 𝑝 = 0.00016) and longer procedure times as well (153.1 ± 32
versus 102±24.8min, resp.;𝑝 = 0.019).Theoverall long-term successwas significantly different between the two groups (68.3 versus
86.7%, resp.; 𝑝 = 0.017). No differences were found in the lesion areas of left and right PV between the two groups (resp., 𝑝 = 0.61
and 0.57). There were no significant differences in procedural-related complications. Conclusion. The ADV catheter compared to
the first-generation balloon allows obtaining a significantly higher success rate after a single PVI procedure during the long-term
follow-up. Fluoroscopy and procedural times were significantly shortened using the ADV catheter.
1. Introduction
Pulmonary vein isolation (PVI) is the cornerstone of any
catheter-based treatment for patients with paroxysmal atrial
fibrillation (PAF) [1, 2]. Electrical isolation is commonly per-
formed by a circumferential lesion set around the pulmonary
veins [1–3].The standard “point-by-point” technique remains
challenging and time-consuming. Cryoballoon (CB) technol-
ogy would theoretically allow PVI with a single application
[4–8]. The first-generation CB, Arctic Front (Medtronic,
Inc., Minneapolis, MN, USA), has been available since
2006 in Europe [7, 8]. With respect to the first-generation
CB, the second-generation, Arctic Front Advance (ADV),
version was designed with technical modifications aiming
at procedural outcome improvement [9–11]. The number of
injection ports has been doubled and these have been placed
more distally on the catheters shaft resulting in a larger and
more uniform zone of freezing on the balloons surface if
compared with the previous version [12]. Aim of the study
was to compare the acute and long-term success of these two
different technologies.
2. Methods
2.1. Patient Population. We retrospectively analyzed 120
patients undergoing PVI using the CB technology who
completed at least 2 years of follow-up. All patients had
symptomatic and drug-resistant PAF according to the current
ESC and HRS/EHRA/ECAS guidelines [1, 2]. Data were
Hindawi Publishing Corporation
Cardiology Research and Practice
Volume 2016, Article ID 5106127, 5 pages
http://dx.doi.org/10.1155/2016/5106127
2 Cardiology Research and Practice
accurately collected for each patient from medical notes
after discharge and included basic demographic, clinical
information, pharmacological therapy, date of hospitalization
and discharge, presence of comorbidities, and cardiovascular
events during hospitalization. From June 2011 to June 2013
sixty patients underwent PVI using the Arctic Front CB
catheter and 60 patients using the ADV ablation catheter.
The 28 mm CB was used in all procedures. In addition,
electroanatomical mapping using NavX Velocity 3.0 system
(St. Jude Medical, Minneapolis, MN, USA) was performed in
a subgroup of patients. The study protocol was approved by
the local Ethics Committee.
2.2. Pulmonary Vein Isolation. All patients underwent pre-
procedural transthoracic echocardiography to asses left ven-
tricular ejection fraction and left atrial dimension. To exclude
the presence of thrombi in the left atrium or in the left atrial
appendage a transesophageal echocardiography was per-
formed the day before the procedure. Moreover, a preproce-
dure magnetic resonance imaging or computed tomography
with segmentation of the left atrium was performed to assess
left atrial anatomy in detail. Procedures were performed
eitherwith continued oral anticoagulation usingwarfarin and
therapeutic INR (2.0 to 3.0) or using low-molecular weight
heparin bridging. All PVI procedures were performed by
experienced operators beyond the learning curve. Briefly,
all procedures were carried out in conscious sedation using
propofol infusion. A deflectable decapolar catheter was
inserted through right femoral vein and positioned into the
coronary sinus to guide the transseptal puncture and to pace
the left atrium during treatment of the left PVs and was
subsequently moved to the superior vena cava where it was
used to stimulate the right phrenic nerve during treatment of
the right PVs. A single transseptal puncture was performed
using a needle system (BRK, St. Jude Medical, St. Paul, MN,
USA) and a standard transseptal sheath (SL0 8F or 8.5F, St.
Jude Medical, St. Paul, MN, USA), subsequently exchanged
with a steerable 15F sheath (FlexCath, 15F, Medtronic,
Inc., Minneapolis, MN, USA). Before transseptal puncture,
heparin was administered intravenously as bolus (10000U)
followed by a continuous infusion (1000U/hr) reaching ACT
level >350 sec. The FlexCath was continuously irrigated with
heparinized saline (2mL/hr). An esophageal temperature
probe was used in all patients (Esotherm Plus, FIAB) to
monitor intraesophageal temperature increase. The probe
was adjusted during the procedure to stay as close as possible
to the ablation catheter. Cryotherapy was interrupted if the
endoluminal esophageal temperature dropped below 18∘C.
Two cryotherapy applications were delivered to each PV,
240–300 seconds each, aiming for a minimum temperature
of less than −40∘C. After treatment of all PVs, entrance
block was confirmed with high-output pacing (12V, 2.9ms)
using the Lasso (Biosense Webster, Diamond Bar, CA,
USA), Afocus (St. Jude Medical, Minneapolis, MN, USA), or
Achieve mapping catheter (Medtronic, Inc., Minneapolis,
MN, USA). “Far field” capture and sensing were ruled out
using differential pacingmaneuvers. Any residual conduction
into the PVs was treated by further cryotherapy applications.
Figure 1: High-density voltage map of the left atrium using elec-
troanatomicmapping, NavXVelocity 3.0, before and after the proce-
dure.
Successful PVI was confirmed when all PV potentials were
abolished or were dissociated at least 20 minutes after the last
cryotherapy application to that vein.
2.3. Lesion Area Comparison. In each patient who under-
went PVI using the electroanatomic mapping system NavX
Velocity 3.0, a high-density voltagemap of the left atriumwas
performed, before and after the procedure, using themapping
catheter Afocus. After cryotherapy, the border between the
scar area and healthy atrial tissue was defined using a 0.1–
0.5mV as offset (0.1mV was defined as scar or absolutely
silent tissue).The border between scar and normal tissue was
defined including both ipsilateral PVs.Using an implemented
tool in the NavX Velocity 3.0, the lesion area (cm2) was
automatically calculated by the system (Figure 1).
2.4. Follow-Up. Patients were followed up in the outpatient
clinic 3 months after the procedure and every 3 months
during the first year after ablation and every 6 months
thereafter. At each visit, a standard 12-lead ECGwas obtained
in all patients. All patients were followed up with Holter-
ECG monitoring at 6 and 12 months and annually after
the PVI procedure. After 90 days of blanking period, any
documented episode of AF or atrial arrhythmias lasting >30
seconds was considered a recurrence. All antiarrhythmic
agents were withdrawn at 3 months after ablation. Clinical
events occurring during the follow-up and documentation
of the events were carefully checked. Clinical success was
defined as complete freedom from symptomatic arrhythmia
and the absence of any atrial arrhythmia during Holter
monitoring.
2.5. Statistical Analysis. Thiswas an observational, retrospec-
tive, single-center study. Continuous variables are reported as
mean ± standard deviation. Comparison of continuous vari-
ables was performed using independent sample Student’s t-
test and categorical data with Fisher’s exact test. Arrhythmia-
free survival curves were generated by the Kaplan-Meier
method and compared with the Log Rank test. Statistical
significancewas consideredwith a𝑝 value of<0.05. SPSS 20.0
statistical software (SPSS Italia, Inc., Florence, Italy) was used
for statistical analysis.
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Table 1: Baseline patient characteristics.
CB, 1st
(𝑛 = 60)
CB, 2nd
(𝑛 = 60) 𝑝
Male sex, 𝑛 (%) 41 (68.3) 50 (83.3) 0.14
Mean age, years (mean ± SD) 59.1 ± 12.2 57.2 ± 10.9 0.37
Body mass index, Kg/m2 (mean ± SD) 26 ± 2 26 ± 3 0.59
Paroxysmal atrial fibrillation, 𝑛 (%) 60 (100) 60 (100) 1
Left atrial diameter, mm (mean ± SD) 22.9 ± 5.1 22.5 ± 4.7 0.60
Left ventricular ejection fraction, (mean ± SD) 62.5 ± 6.1 60.9 ± 7.4 0.72
Hypertension, 𝑛 (%) 25 (41.6) 23 (38.3) 0.63
Hypercholesterolemia, 𝑛 (%) 12 (20) 14 (23.3) 0.61
Diabetes mellitus, 𝑛 (%) 4 (6.6) 5 (8.3) 0.73
Hypertriglyceridemia, 𝑛 (%) 5 (8.3) 6 (10) 0.71
Active smoking, 𝑛 (%) 8 (13.3) 9 (15) 0.69
Coronary artery disease, 𝑛 (%) 4 (6.6) 5 (8.3) 0.73
Dilated cardiomyopathy, 𝑛 (%) 0 0 —
Valve disease, 𝑛 (%) 4 (6.6) 3 (5) 0.40
Previous cardiac surgery, 𝑛 (%) 3 (5) 2 (3.3) 0.46
Previous ischemic stroke, 𝑛 (%) — 1 (1.6) 0.53
Chronic renal failure, 𝑛 (%) 4 (6.6) 3 (5) 0.40
Previous ablation procedures for AF, 𝑛 (%) 0 0 —
Table 2: Fluoroscopy time and procedure time comparison between the first- and second-generation CryoBalloon catheter.
CB, 1st CB, 2nd 𝑝
Procedure time, min (mean ± SD) 153.1 ± 32 102 ± 24.8 0.019
Fluoroscopy time, min (mean ± SD) 36.3 ± 16.8 14.2 ± 13.5 <0.001
3. Results
Baseline clinical characteristics of patients are reported in
Table 1. There were no significant differences between the
2 study groups regarding age, gender, cardiovascular risk
factors, left ventricular ejection fraction, left atrial dimension,
and medical therapy. No significant differences were found
between the two study groups regardingCHA2DS2-VASc and
HAS-BLED scores.
No patients had evidence of left atrial thrombosis during
transesophageal echocardiography. Acute success rate and
procedural-related complications are reported in Table 3.
Procedures performed with the first generation CB showed
longer fluoroscopy time (36.3 ± 16.8 versus 14.2 ± 13.5min,
resp.; 𝑝 < 0.001) and longer procedure times as well (153.1 ±
32 versus 102 ± 24.8min, resp.; 𝑝 = 0.019) compared to the
second-generation ADV catheter (Table 2). Interestingly, no
statistically significant differences were found in the lesion
area of left and right PVc between the two groups (resp., 𝑝 =
0.61 and 0.57, Table 4). The overall success rate after single
PVI procedure including both first- and second-generation
CBwas 77.5%.The long-term freedom-from-AF as showed in
the Kaplan-Meier survival analysis was significantly different
between the two different CB (68.3%with the first-generation
CB versus 86.7% with the second-generation ADV catheter,
resp.; Log Rank 𝑝 = 0.017, Figure 2).
4. Discussion
This retrospective analysis provides data on long-term effi-
cacy of CB ablation performed in a single high-volume center.
The main findings of this study are that the use of the
second-generation ADV catheter significantly improved the
long-term procedural success after single PVI procedure and
reduced procedure duration and fluoroscopy exposure time.
Our results in terms of procedural success using the
first generation CB are in line with those coming from the
North American Arctic Front STOP AF Pivotal Trial (68.3%
versus 69.9% resp.) [13]. Several reports have shown that
CB ablation with the new ADV catheter is associated with
higher success rate of PVI and better outcome. In a first
report of Fu¨rnkranz et al. comparing the first-generation CB
with the ADV, single-shot PVI rate increased from 51% to
84% (𝑝 < 0.001) [12]. Procedure duration and fluoroscopy
exposure time were also significantly decreased using the
novel CB catheter. In a retrospective analysis, Aryana et al.
confirmed thatADVcatheter significantly reduced procedure
time and fluoroscopy time. Freedom from AF at 6, 9, and
12 months was 89, 86, and 82%, respectively, during a mean
follow-up of 16 ± 8 months [14]. Giovanni and coworkers
recently reported a significantly higher freedom from AF at
1-year follow-up with the second-generation ADV catheter
with respect to the first-generation CB. Freedom from AF
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Table 3: Acute success and procedure-related complications.
CB, 1st
(𝑛 = 60)
CB, 2nd
(𝑛 = 60) 𝑝
PVI achieved, (%) 95 98 ns
Catheter failure, 𝑛 (%) 3∗ (5) 1# (1.6) ns
Need of touch-up, 𝑛 (%) 3 (5) 1 (1.6) ns
Acute PNP, 𝑛 (%) 2 (3.3) 1 (1.6) ns
Chronic PNP, 𝑛 (%) 0 0 —
Cerebral embolization, 𝑛 (%) 0 0 —
Pericardial effusion, 𝑛 (%) 1 (1.6) 0 ns
Cardiac tamponade, 𝑛 (%) 0 0 —
PV stenosis, 𝑛 (%) 0 0 —
Atrioesophageal fistula, 𝑛 (%) 0 0 —
Vascular injury, 𝑛 (%) 3 (5) 2 (3.3) ns
PVI: pulmonary vein isolation; PNP: phrenic nerve palsy; #: FlexCath failure; ∗: 2/3 FlexCath failure, 1/3 Cryoballoon failure.
Table 4: Comparison of lesion area between the first- and second-
generation CryoBalloon catheter. Data obtained from electroana-
tomicmapping performed after cryoablation using the NavX system
(St. Jude Medical, St. Paul, MN, USA).
Lesion area CB, 1st CB, 2nd 𝑝
LPVs, cm2 (mean ± SD) 68.2 ± 44 75.3 ± 26 0.61
RPVs, cm2 (mean ± SD) 73.1 ± 33 79.4 ± 22 0.57
LPVs: left pulmonary veins; RPVs: right pulmonary veins.
Time
Freedom-from-AF
1.0
0.8
0.6
0.4
0.2
0.0
0 200 400 600 800
Figure 2: The Kaplan-Meier survival analysis shows a signifi-
cant difference in freedom-from-AF recurrence between patients
undergoing atrial fibrillation ablation using the first-generation
Cryoballoon (CB1) and the second-generation Cryoballoon (CB2)
catheter (Log Rank 𝑝 = 0.017).
off antiarrhythmic drugs (AAD) therapy was achieved in
84% of patients treated with the ADV catheter, compared
to 66% of success rate obtained with first-generation CB
(𝑝 = 0.038). In their experience, procedural and fluoroscopy
times were also significantly decreased by the use of ADV
catheter [15]. Similar findings were reported by Fu¨rnkranz
et al. The authors found freedom from AF after a single
procedure without AAD therapy after 1 year in 63.9% of
patients treated with the first generation of CB versus 83.6%
(𝑝 = 0.008) of patients with the ADV catheter [16]. Liu
et al. during a mean follow-up of 12 ± 4 months found an
overall 76.0% of CB success rate, respectively, 89.7% with
ADV catheter versus 59.7% with the first-generation CB
(𝑝 < 0.001) [17]. In addition to previous published paper,
we performed for the first time a comparison between lesion
areas created by the two different CB. Despite the redesign
of the ADV catheter, in our experience the improved acute
and long-term procedural success seems not to be related to
an increased area of lesion. The main technical limitation of
the first generation CB was the temperature gradient from
the equator to the distal pole of the CB. More specifically,
the first-generation CB had four injection ports positioned
just distal to the equator, cooling the balloon surface with a
temperature gradient with relatively higher temperatures at
the distal pole. As a result, continuous lesions are created if the
balloon is centered in the PV antrum. Differently, eccentric
CB positions may lead to incomplete lesion formation of
tissue, resulting in reconnection gap. Thus, repeated freezing
with different CB positions were often necessary to achieve
PVI prolonging both procedural and fluoroscopy time. The
ADV catheter was redesigned doubling the injection ports
and placing themselves more distally on the catheters shaft
creating a larger and more uniform zone of freezing on the
CB surface. Together, thesemodifications have been shown to
improve procedural and early clinical efficacy during short-
term follow-up. Notably, we report a very low incidence of
procedure-related complications. It could be related to the
size of CB used at our center; indeed we only use the 28
mm balloon due to safety reasons. Creation of proximal
lesions at the antrum of PVs should prevent or at least reduce
complications such as PV stenosis and phrenic nerve palsy.
5. Study Limitations
This study has some limitations: it is a single-center retro-
spective analysis in a highly selected population. In order to
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complete at least 2 years of follow-up, we excluded patients
in which the follow-up was not fully available. Finally, the
follow-up was performed for the majority of patients with
12-lead ECG and Holter-ECG monitoring; unfortunately, an
event recorder was not available for all patients.
6. Conclusion
On the long-term follow-up, PVI using the ADV performs
significantly better when compared to the first-generation
CB. Procedure duration and fluoroscopy exposure time were
significantly shortened with the ADV catheter. Based on
electroanatomical mapping, lesion areas created by the two
CB were not statistically different.
Abbreviations
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